Tempus AI (TEM) Financials: History & Chart

Tempus AI, Inc. (TEM)TEMTempus AI, Inc.

About Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Chicago, IL

3,800 employees

www.tempus.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Eric Lefkofsky

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	1.36B	348.12M	367.21M	334.21M	314.63M	255.74M	200.68M	180.93M	165.97M
Cost of Goods Sold	415.34M	129.78M	37.67M	128.30M	119.60M	100.53M	78.62M	75.09M	90.46M
Gross Profit	948.83M	218.34M	329.54M	205.91M	195.04M	155.20M	122.06M	105.84M	75.51M
Gross Profit Margin	69.6%	62.7%	89.7%	61.6%	62.0%	60.7%	60.8%	58.5%	45.5%
Total Operating Expenses	1.20B	295.66M	377.77M	265.85M	256.81M	223.89M	172.76M	159.46M	609.00M
Research & Development	276.99M	45.92M	71.92M	83.05M	76.10M	69.27M	61.48M	58.03M	145.93M
Selling, General & Administrative	784.62M	212.59M	208.51M	182.80M	180.71M	154.63M	111.29M	101.43M	463.07M
Operating Income (EBIT)	-247.26M	-77.31M	-48.23M	-59.94M	-61.77M	-68.69M	-50.70M	-53.62M	-533.49M
Operating Margin	-18.1%	-22.2%	-13.1%	-17.9%	-19.6%	-26.9%	-25.3%	-29.6%	-321.4%
Income Before Tax (EBT)	-308.48M	-125.98M	-60.16M	-79.71M	-42.63M	-114.22M	-12.89M	-75.80M	-552.12M
Interest Income	14.68M	3.87M	5.12M	4.60M	1.09M	1.81M	3.55M	4.79M	1.72M
Interest Expense	151.20M	14.34M	99.88M	15.40M	21.58M	18.00M	13.36M	13.76M	13.29M
Other Income/Expense	-61.22M	-48.67M	-11.93M	-19.76M	19.14M	-45.53M	37.81M	-22.19M	-18.63M
Net Income	-302.91M	-125.92M	-54.17M	-79.98M	-42.84M	-68.04M	-13.01M	-75.84M	-552.21M
Income Tax Expense	-5.57M	-62K	-5.99M	276K	212K	-46.18M	122K	38K	95K
Net Profit Margin	-22.2%	-36.2%	-14.8%	-23.9%	-13.6%	-26.6%	-6.5%	-41.9%	-332.7%
EBITDA	-139.12M	-51.14M	-21.32M	-32.91M	-33.74M	-48.34M	-41.24M	-44.18M	-524.33M
EBITDA Margin	-10.2%	-14.7%	-5.8%	-9.8%	-10.7%	-18.9%	-20.6%	-24.4%	-315.9%
Depreciation & Amortization	108.15M	26.18M	26.91M	27.03M	28.03M	20.35M	9.46M	9.44M	9.16M
EPS Basic	-1.71	-0.70	-0.30	-0.46	-0.25	-0.40	-0.08	-0.46	-3.66
EPS Diluted	-1.72	-0.71	-0.30	-0.46	-0.25	-0.40	-0.08	-0.46	-3.66
Shares Outstanding	178.88M	178.88M	174.26M	174.94M	173.38M	170.51M	162.12M	165.61M	154.17M
Diluted Shares Outstanding	178.96M	178.96M	174.26M	174.94M	173.38M	170.51M	162.12M	165.61M	154.17M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	1.27B	693.40M	531.82M	320.67M	257.85M	188.00M	62.06M
Cost of Goods Sold	386.10M	312.29M	245.65M	190.48M	174.21M	159.29M	46.02M
Gross Profit	885.69M	381.11M	286.18M	130.19M	83.64M	28.71M	16.04M
Gross Profit Margin	69.6%	55.0%	53.8%	40.6%	32.4%	15.3%	25.9%
Total Operating Expenses	1.12B	1.07B	482.26M	395.63M	327.36M	222.17M	135.82M
Research & Development	146.11M	316.84M	185.50M	162.25M	128.35M	91.28M	56.86M
Selling, General & Administrative	731.74M	755.35M	296.76M	233.38M	199.00M	130.89M	78.96M
Operating Income (EBIT)	-238.63M	-691.08M	-196.08M	-265.44M	-243.71M	-193.45M	-119.78M
Operating Margin	-18.8%	-99.7%	-36.9%	-82.8%	-94.5%	-102.9%	-193.0%
Income Before Tax (EBT)	-296.71M	-705.54M	-213.83M	-289.75M	-259.19M	-209.85M	-114.95M
Interest Income	12.63M	11.08M	7.60M	3.03M	623K	1.50M	4.86M
Interest Expense	70.27M	53.65M	46.87M	21.89M	15.18M	18.93M	28K
Other Income/Expense	-58.08M	-14.46M	-17.75M	-24.30M	-15.48M	-16.40M	4.83M
Net Income	-245.03M	-705.81M	-214.12M	-289.81M	-259.19M	-209.85M	-114.95M
Income Tax Expense	-51.68M	266K	288K	66K	0.00	0.00	0.00
Net Profit Margin	-19.3%	-101.8%	-40.3%	-90.4%	-100.5%	-111.6%	-185.2%
EBITDA	-234.55M	-653.84M	-162.75M	-235.03M	-219.83M	-170.40M	-104.76M
EBITDA Margin	-18.4%	-94.3%	-30.6%	-73.3%	-85.3%	-90.6%	-168.8%
Depreciation & Amortization	4.09M	37.24M	33.33M	30.41M	23.88M	23.05M	15.02M
EPS Basic	-1.41	-4.60	-1.73	-1.97	-1.75	-1.49	-0.92
EPS Diluted	-1.41	-4.60	-1.73	-1.97	-1.75	-1.49	-0.92
Shares Outstanding	174.26M	162.12M	154.17M	169.88M	169.88M	169.88M	160.71M
Diluted Shares Outstanding	174.26M	162.12M	154.17M	169.88M	169.88M	169.88M	160.71M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.